Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 56Etoposide 40Filgrastim 37Carboplatin 34Vincristine 30Doxorubicin 30Melphalan 27Topotecan 25Isotretinoin 24Peripheral Blood Stem Cell Transplantation 23Granulocyte Colony-Stimulating Factor 22Cisplatin 21Irinotecan 20sargramostim 18Temozolomide 17humanized 3F8 anti-GD2 monoclonal antibody 15Radiotherapy 153-Iodobenzylguanidine 13Granulocyte-Macrophage Colony-Stimulating Factor 11Busulfan 11dinutuximab 10Interleukin-2 9aldesleukin 8Thiotepa 8Ifosfamide 8etoposide phosphate 7Mesna 7Vorinostat 6Stem Cell Transplantation 6Polymerase Chain Reaction 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroblastoma × lestaurtinib × Clear all
NCT00084422 2023-04-10

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
47 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡